Skip to main content
300 Collins St Melbourne
hello@pivot.net
Login
Signup
Main navigation
About
Team
Contact
Research & Development
Innovation Engine
Therapeutic Focus
Development Strategy
Publications/Presentations
Pipeline
RMC-4630
Mutant RAS
SOS1
RMC-5552
Investors
Careers
Publications/Presentations
Publication / Presentation
October 24, 2020
Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling
Read more
Publication / Presentation
September 29, 2020
Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity
Read more
Publication / Presentation
June 22, 2020
Dual inhibition of SHP2 and CDK4/6 leads to immunological memory and immune-mediated anti-tumor activity in a mouse syngeneic model of breast cancer
Read more
Publication / Presentation
June 22, 2020
Positioning a selective, bi-steric inhibitor of mTORC1 as a combination partner in RAS-driven cancers
Read more
Publication / Presentation
June 22, 2020
Discovery and development of allosteric inhibitors of SHP2
Read more
